Skip to main content
SpringerLink
Log in

Chemotherapy for Breast Cancer

  • Chapter
Breast Cancer

Part of the book series: M. D. Anderson Cancer Care Series ((MDCCS))

Abstract

Over the past 30 years, numerous advances have contributed to improved survival for patients with breast cancer. Many of these advances involve the development and use of systemic chemotherapy in the adjuvant and metastatic settings. In terms of patient survival, anthracycline-containing regimens are superior to non-anthracycline-containing regimens. The optimal use of taxanes in the adjuvant setting is under continued investigation. In general, anthracyclines and taxanes are the cornerstones of the treatment paradigm employed at M. D. Anderson Cancer Center.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Readings

  • A’Hern RP, Smith IE, Ebbs SR. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993; 67: 801–805.

    Article  PubMed  Google Scholar 

  • Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599–605.

    PubMed  CAS  Google Scholar 

  • American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996; 14: 1957–1960.

    Google Scholar 

  • Blum JL, Buzdar AU, LoRusso PM, et al. A multicenter phase II trial of Xeloda (capecitabine) in paclitaxel-refractory metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1998; 17: 125A.

    Google Scholar 

  • Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405–410.

    Article  PubMed  CAS  Google Scholar 

  • Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995a; 332: 901–906.

    Article  PubMed  CAS  Google Scholar 

  • Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995b; 273: 542–547.

    Article  PubMed  CAS  Google Scholar 

  • Burris HA III. Single-agent docetaxel (Taxotere) in randomized phase III trials. Semin Oncol 1999; 26 (suppl 9): 1–6.

    PubMed  CAS  Google Scholar 

  • Burstein HJ, Younger J, Bunnell CA, et al. Weekly docetaxel (Taxotere) for metastatic breast cancer: a phase II trial. Proceedings of the American Society of Clinical Oncology 1999;18:127A. Abstract 484.

    Google Scholar 

  • Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 1989; 12: 123–128.

    Article  PubMed  CAS  Google Scholar 

  • Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999; 17: 3412–3417.

    PubMed  CAS  Google Scholar 

  • Buzdar AU, Smith TL, Powell KC, Blumenschein GR, Gehan EA. Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat 1982; 2: 163–169.

    Article  PubMed  CAS  Google Scholar 

  • Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731–2736.

    PubMed  CAS  Google Scholar 

  • Casper ES, Guidera CA, Bosl GJ, et al. Combined modality treatment of locally advanced breast cancer: adjuvant combination chemotherapy with and without doxorubicin. Breast Cancer Res Treat 1987; 9: 39–44.

    Article  PubMed  CAS  Google Scholar 

  • Chen YY, Schnitt SJ. Prognostic factors for patients with breast cancers 1 cm and smaller. Breast Cancer Res Treat 1998; 51: 209–225.

    Article  PubMed  CAS  Google Scholar 

  • Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987; 317: 1490–1495.

    Article  PubMed  CAS  Google Scholar 

  • Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 over-expression who relapsed following chemotherapy for metastatic breast cancer. Proceedings of the American Society of Clinical Oncology 1998; 17: 97A.

    Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930–942.

    Google Scholar 

  • Ejlertsen B, Pfeiffer P, Pedersen D, et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 1993; 29A: 527–531.

    Article  Google Scholar 

  • Falkson G, Gelman RS, Pandya KJ, et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 1998; 16: 1669–1676.

    PubMed  CAS  Google Scholar 

  • Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicincyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990a; 8: 1483–1496.

    PubMed  CAS  Google Scholar 

  • Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672–2685.

    PubMed  CAS  Google Scholar 

  • Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89: 1673–1682.

    Article  PubMed  CAS  Google Scholar 

  • Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990b; 8: 1005–1018.

    PubMed  CAS  Google Scholar 

  • Fisher B, Slack N, Katrych D, Wolmark N. Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 1975; 140: 528–534.

    PubMed  CAS  Google Scholar 

  • Fossati R, Confalonieri C, Torn V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16: 3439–3460.

    PubMed  CAS  Google Scholar 

  • Gralla RJ, Osoba D, Kris MG, Kirkbride P, et al. Recommendations for the use of antiemetics: evidence-based clinical practice guidelines. J Clin Oncol 1999; 17: 2971–2994.

    PubMed  CAS  Google Scholar 

  • Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Longterm follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197–2205.

    PubMed  CAS  Google Scholar 

  • Gregory RK, Powles TJ, Chang JC, Ashley S. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 1997; 33: 2194–2197.

    Article  PubMed  CAS  Google Scholar 

  • Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10: 1049–1056.

    PubMed  CAS  Google Scholar 

  • Henderson IC, Berry D, Demetri G, et al. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proceedings of the American Society of Clinical Oncology 1998;17:101A. Abstract 390.

    Google Scholar 

  • Holmes FA, Valero V, Walters RS, et al. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol 1999; 10: 403–411.

    Article  PubMed  CAS  Google Scholar 

  • Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797–1805.

    Article  PubMed  CAS  Google Scholar 

  • Hortobagyi GN, Frye D, Buzdar AU, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 1989; 63: 37–45.

    Article  PubMed  CAS  Google Scholar 

  • Hutchins L, Green S, Ravdin P, et al. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history followup study in low-risk node-negative patients: first results of intergroup trial INT 0102. Proceedings of the American Society of Clinical Oncology 1998;17. Abstract 1.

    Google Scholar 

  • Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 2000; 320: 474–478.

    Article  PubMed  CAS  Google Scholar 

  • Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: 2651–2658.

    PubMed  CAS  Google Scholar 

  • Mamounas E, Brown A, Smith R, et al. Effect of taxol duration of infusion in advanced breast cancer (ABC): results from NSABP B-26 trial comparing 3-to 24-h infusion of high-dose taxol. Proceedings of the American Society of Clinical Oncology 1998; 17: 101A.

    Google Scholar 

  • Muss HB, Case LD, Richards F III, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 1991; 325: 1342–1348.

    Article  PubMed  CAS  Google Scholar 

  • Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260–1266.

    Google Scholar 

  • Nabholtz JM. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer. Semin Oncol 1999; 26 (suppl 9): 7–13.

    PubMed  CAS  Google Scholar 

  • Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1858–1867.

    PubMed  CAS  Google Scholar 

  • Norton L, Slamon D, Leyland-Jones B, et al. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2 overexpressing (HER2 +) metastatic breast cancer (MBC). Proceedings of the American Society of Clinical Oncology 1999;18:127A. Abstract 483.

    Google Scholar 

  • Rahman ZU, Frye DK, Smith TL, et al. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer 1999; 85: 104–111.

    Article  PubMed  CAS  Google Scholar 

  • Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996; 334: 1356–1361.

    Article  PubMed  CAS  Google Scholar 

  • Rosen PP, Groshen S, Kinne DW. Prognosis in T2NOMO stage I breast carcinoma: a 20-year follow-up study. J Clin Oncol 1991; 9: 1650–1661.

    PubMed  CAS  Google Scholar 

  • Seidman AD. Single-agent paclitaxel in the treatment of breast cancer: phase I and II development. Semin Oncol 1999; 26 (suppl 8): 14–20.

    PubMed  CAS  Google Scholar 

  • Slamon DJ, Clark GM, Wong SG, Levin J, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 1987; 235: 177–182.

    Article  PubMed  CAS  Google Scholar 

  • Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized antiHER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2 + /MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proceedings of the American Society of Clinical Oncology 1998;17:98A. Abstract 377.

    Google Scholar 

  • Sledge G, Neuberg D, Ingle J, Martino S, Wood W. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proceedings of the American Society of Clinical Oncology 1997;16:1A. Abstract 2.

    Google Scholar 

  • Stockler M, Wilcken N, Coates A. Chemotherapy for metastatic breast cancer—when is enough enough? Eur J Cancer 1997; 33: 2147–2148.

    Article  PubMed  CAS  Google Scholar 

  • Terenziani M, Demicheli R, Brambilla C, et al. Vinorelbine: an active, non cross-resistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat 1996; 39: 285–291.

    Article  PubMed  CAS  Google Scholar 

  • Thomas E, Buzdar A, Theriault R, et al. Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of prospective randomized clinical trial. Proceedings of the American Society of Clinical Oncology 2000;19. Abstract 285.

    Google Scholar 

  • Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracyclineresistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886–2894.

    PubMed  CAS  Google Scholar 

  • Winer E, Berry D, Duggan D, et al. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer—results from CALGB 9342. Proceedings of the American Society of Clinical Oncology 1998; 17: 101A.

    Google Scholar 

  • Zambetti M, Bonadonna G, Valagussa P, et al. Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients. J Natl Cancer Inst Monogr 1992;(11):77–83.

    Google Scholar 

Download references

Authors
  1. Marjorie C. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriel N. Hortobagyi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgical Oncology, M. D. Anderson Cancer Center, The University of Texas, 77030-4009, Houston, TX, USA

    Kelly K. Hunt M.D.

  2. Department of Plastic Surgery, M. D. Anderson Cancer Center, The University of Texas, 77030-4009, Houston, TX, USA

    Geoffrey L. Robb M.D.

  3. Department of Radiation Oncology, M. D. Anderson Cancer Center, The University of Texas, 77030-4009, Houston, TX, USA

    Eric A. Strom M.D.

  4. Department of Blood and Marrow Transplantation, M. D. Anderson Cancer Center, The University of Texas, 77030-4009, Houston, TX, USA

    Naoto T. Ueno M.D., Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Green, M.C., Hortobagyi, G.N. (2001). Chemotherapy for Breast Cancer. In: Hunt, K.K., Robb, G.L., Strom, E.A., Ueno, N.T. (eds) Breast Cancer. M. D. Anderson Cancer Care Series. Springer, New York, NY. https://doi.org/10.1007/978-0-387-21842-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-21842-7_11

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-95190-4

  • Online ISBN: 978-0-387-21842-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation